When the heart and the mind collide: Cardiovascular risk factors and antipsychotic use in the schizophrenic population

Journal of the CardioMetabolic Syndrome

Volumn 4, Issue 1, 2009, Pages 1-5

  Halpert, Sari ^a   McFarlane, Samy I ^a  

^a KINGS COUNTY HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

AGRANULOCYTOSIS; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD HEALTH CARE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; GENETIC PREDISPOSITION; HEREDITY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; POLYPHARMACY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CHILD; HUMANS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 61349134276     PISSN: 15594564     EISSN: 15594572     Source Type: Journal    
DOI: 10.1111/j.1559-4572.2008.00049.x     Document Type: Editorial

References (26)

1. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
2. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349.
3. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
4. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86(2):713-718.
5. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: The metabolic syndrome. Life Sci. 2002;71:239-257.
6. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
7. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
8. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369-374.
9. Paton C, Esop R, Young C, et al. Obesity, dyslipidaemia and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand. 2004;110:299-305.
10. Gianfrancesco FD, White R, Wang R, et al. Antipsychotic-induced type 2 diabetes: Evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328-335.
11. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
12. Castro JP, El-Atat FA, McFarlane SI, et al. Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep. 2003;5(5):393-401.
13. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-689.
14. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
15. Lorenz WF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry. 1922;8:184-196.
16. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-289.
17. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Rev Arch Gen Psychiatry. 2002;59:337-345.
18. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289-297.
19. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care. 2002;25(4):718-723.
20. Patel NC, Kistler JS, James EB, et al. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy. 2004;24:824-830.
21. Casey D. Long-term weight profile of stable patients with schizophrenia receiving bifeprunox. Abstract NR484. Presented at the Annual Meeting of the American Psychiatric Association. May 19, 2007; San Diego, CA.
22. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. J Clin Psychiatry. 2006;67:1253-1260.
23. Barrett E, Blonde L, Clement S, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
24. Barnett AH, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007;21:357-273.
25. Wu RR, Zhao JP, Jin H, et al. Lifestyle Intervention and metformin for the treatment of antipsychotic-induced weight gain: A randomized controlled trial. JAMA. 2008;299(2):185-193.
26. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med. 2002;137(1):25-33.